Patents Assigned to Merck Sharp & Dohme LLC
  • Pro drugs of PDE10 compounds
    Patent number: 11919894
    Abstract: The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: March 5, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Sachin Mittal, Jason W. Skudlarek, Izzat T. Raheem
  • AMIDO-SUBSTITUTED PYRIDYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240067657
    Abstract: The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R7, and R8 are as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 21, 2021
    Publication date: February 29, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Kira A. Armacost, Richard Thaddeus Berger, Jr., Andrew J. Cooke, Christopher Douglas Cox, Brendan M. Crowley, Marc Labroli, Michael Aaron Plotkin, Izzat Tiedje Raheem, Anthony W. Shaw, Kelly-Ann S. Schlegel, Jason W. Skudlarek, Ling Tong
  • NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS
    Publication number: 20240059700
    Abstract: Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
    Type: Application
    Filed: September 12, 2023
    Publication date: February 22, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Yeon-Hee Lim, Jianming Bao, Faben A. Cruz, Fa-Xiang Ding, Cedric Lorenz Hugelshofer, Victor W. Mak, James Patrick Roane, Jillian R. Sanzone, Samantha E. Shockley, Rose Yen
  • FUSED BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240059693
    Abstract: The present invention relates to novel Fused Bicyclic Pyrazole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are as defined herein. The present invention also relates to compositions comprising at least one Fused Bicyclic Pyrazole Derivative, and methods of using the Fused Bicyclic Pyrazole Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 22, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Ronald K. Chang, Andrew J. Cooke, JR., Christopher Douglas Cox, Marc Labroli, Izzat Tiedje Raheem, Jack D. Scott, Jeffrey W. Schubert, Jason W. Skudlarek, Zheng Tan, Ling Tong
  • FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
    Publication number: 20240052036
    Abstract: The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
    Type: Application
    Filed: October 12, 2023
    Publication date: February 15, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Preeti G. Desai, Shuai Shi, Valentyn Antochshuk, Rubi Burlage, Smita Raghava
  • FUSED [7,5] BICYCLIC PYRAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF HERPESVIRUSES
    Publication number: 20240051963
    Abstract: The present invention relates to novel Fused [7,5] Bicyclic Pyrazole Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, and R4 are as defined herein. The present invention also relates to compositions comprising at least one Fused [7,5] Bicyclic Pyrazole Derivative, and methods of using the Fused [7,5] Bicyclic Pyrazole Derivatives for treating or preventing a herpesvirus infection in a patient.
    Type: Application
    Filed: December 9, 2021
    Publication date: February 15, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Andrew J. Cooke, JR., Jeffrey W. Schubert, Jason W. Skudlarek
  • LIPID NANOPARTICLE COMPOSITIONS CONTAINING MONOESTER CATIONIC LIPIDS
    Publication number: 20240050378
    Abstract: The present disclosure provides, among other things, lipid nanoparticle formulations that include monoester cationic lipids. The present invention also provides compositions that include monoester cationic lipid nanoparticles and nucleic acids. The present disclosure also provides lipid nanoparticles encapsulating agents. The present disclosure further provides methods of producing lipid nanoparticles with encapsulated nucleic acids.
    Type: Application
    Filed: December 1, 2021
    Publication date: February 15, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Marian E. Gindy, Andrew Bett, Izzat Tiedje Raheem, Ronald M. Kim
  • Anti-ILT4 antibodies and antigen-binding fragments
    Patent number: 11897957
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: February 13, 2024
    Assignees: Merck Sharp & Dohme LLC, Agenus Inc.
    Inventors: Milan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga
  • Theoretical modeling and mechanism of drug release from controlled release implants by microstructural image characterization
    Patent number: 11900025
    Abstract: Embodiments disclosed herein relate to a model for predicting the release profile of a controlled release device. The implant modeling system and models disclosed herein allow the accurate prediction of a release profile for a controlled release device based on features extracted from micro-resolution imagery. The models combine microstructural features that can be extracted at the XRCT resolution, including pore volume and connectivity, using erosion-dilation image analysis. This strategy allows prediction of release curves of the controlled release device using XRCT despite its resolution limitations.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: February 13, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Roberto Irizarry, Antong Chen, Daniel Skomski
  • Anti-ILT4 antibodies and antigen-binding fragments
    Patent number: 11897956
    Abstract: The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody. Also provided are methods of use thereof, for example, for treating or preventing cancer in a subject; and methods of making such antibodies and fragments.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: February 13, 2024
    Assignees: Merck Sharp & Dohme LLC, Agenus Inc.
    Inventors: Milan Blanusa, Barbara Joyce-Shaikh, Andrea Claudia Schuster, Kornelia Schultze, Luis A. Zuniga
  • MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF
    Publication number: 20240041882
    Abstract: The present invention relates to oral dosage forms comprising letermovir and, in particular, to compressed mini-tablets comprising letermovir. The invention also relates to methods of using the oral dosage forms for the treatment, prevention, or prophylaxis of HCMV in a patient. In addition, the invention also provides methods for making the mini-tablets of the invention.
    Type: Application
    Filed: December 14, 2021
    Publication date: February 8, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Cory Bottone, Andrew J. Gmitter, Ashley R. Johnson, Eric A. Kemp, Feng Li, Fochive Njikam, Michael H. Wang
  • TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS
    Publication number: 20240043402
    Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula (I) and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naive cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
    Type: Application
    Filed: December 6, 2021
    Publication date: February 8, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Antonella Converso, David N. Hunter, Abdellatif El Marrouni, Anthony J. Roecker, Anthony W. Shaw, William D. Shipe, Cheng Wang, Deping Wang, Yunlong Zhang
  • Formulations of dengue virus vaccine compositions
    Patent number: 11883480
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • Methods for production of capsular polysaccharide protein conjugates from serotype 19F
    Patent number: 11883502
    Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael Albert Winters, John E. MacNair
  • Tricyclic heterocycle compounds useful as HIV integrase inhibitors
    Patent number: 11884683
    Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Tao Yu, Alan Whitehead, Yili Chen, Chunrui Sun, Zhiyong Hu, Kake Zhao, Ronald M. Kim, John A. McCauley
  • Phosphonate linkers and their use to facilitate cellular retention of compounds
    Patent number: 11883500
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • ASEPTIC MANIFOLD DISPENSING ASSEMBLY
    Publication number: 20240025577
    Abstract: An aseptic manifold dispensing assembly that comprises a connector for connecting to a source, a dispensing manifold in fluid communication with the connector that includes a plurality of outputs, and a filling manifold. The filling manifold comprises an inlet for connecting to at least one of the plurality of outputs of the dispensing manifold, a plurality of peristaltic pumps connected in parallel downstream the inlet, and a container downstream the plurality of peristaltic pumps, a scale, and a controller operatively connected to the scale and the filling manifold.
    Type: Application
    Filed: December 9, 2021
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: David J. Ostermayer, Marcus Skaflen, Edmond C. Menegaux, Robert Boulanger, Kelsey M. FitzGerald, Annette Krysiewicz, Paul M. Breza, Bogdan Tehlewicz, Abhay C. Kirpekar
  • PLASMA KALLIKREIN INHIBITORS
    Publication number: 20240025917
    Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Jianming Bao, Natalija Cernaka, Alan C. Cheng, Ying-Duo Gao, Salman Jabri, Jovan Alexander Lopez, Rohan Merchant, Anthony Ken Ogawa, Skylar K. Osler, Christopher J. Sinz, Phillip Patrick Sharp, Haiqun Tang, Maoqun Tian, Dong Xiao, Song Yang
  • METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIES
    Publication number: 20240026003
    Abstract: The present invention relates to methods for treating cancer in a patient comprising administering a PD-1 antagonist, e.g., an anti-PD-1 antibody or antigen binding fragment thereof (e.g. pembrolizumab), in specific amounts to the patient about every six weeks. In some embodiments, the amount of anti-PD-1 antibody or antigen binding fragment thereof is about 400 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits comprising a dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Mallika Lala, Lokesh Jain, Mengyao Li
  • RIPK1 INHIBITORS AND METHODS OF USE
    Publication number: 20240025912
    Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.
    Type: Application
    Filed: May 17, 2023
    Publication date: January 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Joanna L. Chen, Yi-Heng Chen, Erin F. DiMauro, Min Liu, Joey L. Methot, Andrew J. Musacchio, Anandan Palani, Barbara Pio, Lorena Rico Duque, Phieng Siliphaivanh, Brandon A. Vara